Nunzia Pharmaceutical Company (NUNZ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nunzia Pharmaceutical Company (NUNZ) trades at $0.0001 with AI Score 47/100 (Grade C). Nunzia Pharmaceutical Company focuses on manufacturing and distributing its nutraceutical product, Nunzia, targeting disorders like autism and ADHD. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for NUNZ: NUNZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NUNZ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NUNZ: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nunzia Pharmaceutical Company (NUNZ) Healthcare & Pipeline Overview
Nunzia Pharmaceutical Company, formerly Arizona Gold and Onyx Mining, manufactures and distributes Nunzia, a nutraceutical targeting autism, ADHD, and PTSD. Operating in the specialty and generic drug sector, the company utilizes wholesalers and its website for distribution, facing competition in a market with established pharmaceutical players.
What Is the Investment Thesis for NUNZ?
Nunzia Pharmaceutical Company presents a high-risk, high-reward investment profile. The company's focus on a single nutraceutical product, Nunzia, creates both opportunity and vulnerability. Potential catalysts include positive clinical data supporting Nunzia's efficacy in treating target disorders, which could drive increased demand and revenue growth. However, the company's small market capitalization and limited financial resources pose significant risks. Successful expansion hinges on effective marketing, strategic partnerships, and navigating the regulatory landscape for nutraceuticals. Investors should closely monitor the company's cash flow, sales growth, and ability to secure additional funding to sustain operations.
Based on FMP financials and quantitative analysis
NUNZ Key Highlights
Nunzia Pharmaceutical Company's sole product is Nunzia, a nutraceutical targeting autism, fragile X, ADHD, and PTSD.
- The company distributes its product through wholesalers and its website, nunziapharma.com.
- Nunzia Pharmaceutical Company was formerly known as Arizona Gold and Onyx Mining Company, changing its name in 2018.
- The company's market capitalization is $0.00B as of 2026-03-18.
- The company's beta is -3.28, indicating high volatility relative to the market.
Who Are NUNZ's Competitors?
NUNZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NUNZ's Key Strengths?
Proprietary nutraceutical product (Nunzia).
- Direct-to-consumer sales channel via website.
- Focus on specific disorders (autism, ADHD, PTSD).
- Established manufacturing and distribution rights for Nunzia.
What Are NUNZ's Weaknesses?
Limited product portfolio (single product dependency).
- Small market capitalization.
- Limited financial resources.
- Dependence on wholesalers for distribution.
What Could Drive NUNZ Stock Higher?
Potential positive clinical data release regarding Nunzia's efficacy in treating target disorders.
- Expansion of online marketing and sales efforts to increase brand awareness and customer acquisition.
- Strategic partnerships with healthcare providers to integrate Nunzia into established treatment protocols.
What Are the Key Risks for NUNZ?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies with greater resources and established market presence.
- Regulatory scrutiny regarding the marketing and labeling of Nunzia as a nutraceutical.
- Adverse events or safety concerns associated with Nunzia, leading to product recalls or lawsuits.
- Limited financial resources and dependence on external funding to sustain operations.
- The company's OTC listing presents liquidity and transparency challenges.
What Are the Growth Opportunities for NUNZ?
- Expanding Online Sales: Nunzia Pharmaceutical Company can focus on enhancing its online presence and direct-to-consumer sales through its website, nunziapharma.com. By improving website usability, implementing targeted digital marketing campaigns, and offering personalized customer service, the company can attract a wider customer base and increase sales. The global e-commerce market is projected to reach $6.3 trillion in 2026, providing a significant opportunity for Nunzia to capture a larger share of online nutraceutical sales. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Collaborating with healthcare providers, such as doctors, therapists, and clinics specializing in autism, ADHD, and PTSD, can significantly boost Nunzia's market reach and credibility. By offering educational resources, product samples, and referral programs, Nunzia can integrate its product into established treatment protocols and gain the trust of healthcare professionals. This strategy can lead to increased product adoption and long-term customer loyalty. Timeline: Ongoing.
- Geographic Expansion: Nunzia Pharmaceutical Company can explore expanding its market presence beyond its current distribution channels by targeting new geographic regions. Conducting market research to identify areas with high demand for nutraceuticals and unmet needs in the treatment of autism, ADHD, and PTSD can guide the company's expansion efforts. This could involve establishing partnerships with local distributors, participating in regional trade shows, and adapting its marketing materials to suit local cultures and languages. Timeline: 1-2 years.
- Product Line Extension: While Nunzia currently focuses on a single product, the company can explore developing and launching complementary nutraceutical products targeting related health conditions or specific age groups. This could involve formulating new products with different ingredients, dosages, or delivery methods to cater to a wider range of customer needs and preferences. Expanding the product line can increase revenue streams and reduce the company's reliance on a single product. Timeline: 2-3 years.
- Clinical Research and Validation: Investing in clinical research to scientifically validate the efficacy of Nunzia in treating autism, ADHD, and PTSD can significantly enhance the product's credibility and market acceptance. Conducting clinical trials, publishing research findings in peer-reviewed journals, and obtaining endorsements from reputable medical organizations can build trust among healthcare professionals and consumers. This can lead to increased product recommendations and sales. Timeline: Ongoing.
What Are NUNZ's Competitive Advantages?
- Proprietary Formulation: Nunzia Pharmaceutical Company owns the rights to manufacture, market, and distribute Nunzia.
- Brand Recognition: Brand recognition, if established, within the niche market of nutraceuticals for specific disorders.
- Direct-to-Consumer Channel: Direct sales through the company's website, nunziapharma.com.
What Does NUNZ Do?
Nunzia Pharmaceutical Company, originally incorporated in 1986 as Arizona Gold and Onyx Mining Company, underwent a significant transformation in February 2018 when it rebranded to focus on the pharmaceutical and nutraceutical industry. Headquartered in Long Beach, California, Nunzia specializes in the manufacturing, marketing, and distribution of its proprietary nutraceutical product, Nunzia. This product is formulated to address symptoms associated with various disorders, including autism, fragile X syndrome, ADHD, and PTSD. Nunzia Pharmaceutical Company primarily distributes its product through two channels: wholesalers and its direct-to-consumer online platform, nunziapharma.com. This dual approach aims to maximize market reach and cater to different customer preferences. The company's transition from mining to pharmaceuticals reflects a strategic shift towards a sector with potentially higher growth and societal impact. However, it also entails navigating the complex regulatory landscape and competitive dynamics of the pharmaceutical industry. As a relatively small player, Nunzia faces the challenge of establishing brand recognition and market share against larger, more established pharmaceutical companies.
What Products and Services Does NUNZ Offer?
- Manufactures Nunzia, a nutraceutical product.
- Markets Nunzia for the treatment of autism.
- Markets Nunzia for the treatment of fragile X syndrome.
- Markets Nunzia for the treatment of ADHD.
- Markets Nunzia for the treatment of PTSD.
- Distributes Nunzia through wholesalers.
- Distributes Nunzia through its website, nunziapharma.com.
How Does NUNZ Make Money?
- Develops and manufactures the nutraceutical Nunzia.
- Sells Nunzia through wholesale distribution channels.
- Generates revenue through direct-to-consumer sales via its website.
What Industry Does NUNZ Operate In?
Nunzia Pharmaceutical Company operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving regulatory standards. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for affordable medications. Companies like ARYX and ATTBF represent established players in this space. Nunzia's success depends on differentiating its nutraceutical product and effectively targeting specific patient populations. The nutraceutical market is experiencing growth, but faces scrutiny regarding product claims and efficacy.
Who Are NUNZ's Key Customers?
- Individuals with autism and their families.
- Individuals with fragile X syndrome and their families.
- Individuals with ADHD and their families.
- Individuals with PTSD.
- Wholesale distributors of nutraceutical products.
Financial Health
Nunzia Pharmaceutical Company's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Nunzia Pharmaceutical Company (NUNZ) Valuation Context
Relative to its peer group, NUNZ's quantitative score of 47/100 is below the peer average of 62/100.
Company Profile
Nunzia Pharmaceutical Company operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Long Beach, US. The company is led by CEO Sara Gonzales. NUNZ has traded publicly since 2009.
NUNZ Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Nunzia's future prospects, suggesting that management believes in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting Nunzia's innovative drug pipeline as a game changer in the pharmaceutical sector.
- Analysts have noted increased interest in Nunzia's research collaborations, which could lead to significant breakthroughs and market opportunities.
- The recent regulatory developments have been favorable, positioning Nunzia to capitalize on upcoming product launches.
Bear Case
- Despite recent positive sentiment, some analysts express concerns about the competitive landscape, which could impact Nunzia's market share.
- There are lingering doubts about the timeline for product approvals, as delays could hinder revenue generation and investor confidence.
- Community discussions reveal skepticism regarding the sustainability of Nunzia's current growth, with some fearing it may be overhyped.
- Recent market volatility has caused some investors to reassess their positions, leading to a cautious outlook on Nunzia's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NUNZ Latest News
No recent news available for NUNZ.
NUNZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NUNZ.
Price Targets
Wall Street price target analysis for NUNZ.
NUNZ MoonshotScore
What does this score mean?
The MoonshotScore rates NUNZ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sara Gonzales
CEO
Sara Gonzales serves as the CEO of Nunzia Pharmaceutical Company. Information regarding her detailed career history, educational background, and previous roles is not available in the provided data. Therefore, a comprehensive profile cannot be constructed at this time. Further research would be needed to ascertain her specific expertise and qualifications for leading the company.
Track Record: Due to the limited information available, it is not possible to assess Sara Gonzales's track record or highlight any specific achievements or strategic decisions made under her leadership. A thorough evaluation would require access to company performance data, strategic initiatives, and other relevant information.
NUNZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nunzia Pharmaceutical Company may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures to the public. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited or no financial disclosures.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or misrepresentation.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Determine the company's capital structure and debt levels.
- Understand the risks associated with the OTC Other market.
- Consult with a qualified financial advisor.
- Company website and contact information.
- Independent verification of business operations.
- Any available press releases or news articles.
- Third-party reports or ratings (if available).
- Clear and transparent communication from management.
What Investors Ask About Nunzia Pharmaceutical Company (NUNZ) — Healthcare
What does the AI Score mean for NUNZ?
NUNZ holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Nunzia Pharmaceutical Company focuses on manufacturing and distributing its nutraceutical product, Nunzia, targeting disorders like autism and ADHD. The company operates through wholesalers and its …
What does Nunzia Pharmaceutical Company do?
Nunzia Pharmaceutical Company is a pharmaceutical and nutraceutical company focused on manufacturing and distributing its proprietary nutraceutical product, Nunzia. Nunzia is marketed as a treatment for various disorders, including autism, fragile X syndrome, ADHD, and PTSD. The company distributes its product through wholesalers and directly to consumers through its website, nunziapharma.com. Formerly known as Arizona Gold and Onyx Mining Company, Nunzia Pharmaceutical Company transitioned to the pharmaceutical sector in 2018.
What are the main risks for NUNZ?
Nunzia Pharmaceutical Company faces several key risks, including its reliance on a single product, Nunzia, and its small market capitalization. Competition from larger pharmaceutical companies poses a significant threat. Regulatory scrutiny of nutraceutical claims and potential adverse events associated with Nunzia could also negatively impact the company.
What are the key factors to evaluate for NUNZ?
Nunzia Pharmaceutical Company (NUNZ) holds an AI score of 47/100 (low). Nunzia Pharmaceutical Company presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does NUNZ data refresh on this page?
NUNZ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NUNZ's recent stock price performance?
Nunzia Pharmaceutical Company (NUNZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary nutraceutical product (Nunzia). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NUNZ overvalued or undervalued right now?
Nunzia Pharmaceutical Company (NUNZ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NUNZ before investing?
Before investing in Nunzia Pharmaceutical Company (NUNZ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NUNZ to a portfolio?
Key strength of Nunzia Pharmaceutical Company (NUNZ): Proprietary nutraceutical product (Nunzia). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market carries inherent risks and uncertainties.